Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 2 Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK; 3 Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK; 4 South London and Maudsley NHS Foundation Trust, London, UK; 5 Division of Psychiatry, Institute of Mental Health, University College London, London, UK
Список исп. литературыСкрыть список 1. Merritt K, Egerton A, Kempton MJ et al. Nature of glutamate alterations in schizophrenia. JAMA Psychiatry 2016;73:665-74. 2. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77. 3. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15. 4. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 2020;19:15-33. 5. McCutcheon R, Beck K, Jauhar S et al. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull 2018;44:1301-11. 6. Howes OD, Kambeitz J, Stahl D et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012;69:776-86. 7. Abi-Dargham A, Rodenhiser J, Printz D et al. Increased baseline occupancy of D 2 -receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000;97:8104-9. 8. Slifstein M, Abi-Dargham A. Is it preor postsynaptic? Imaging striatal dopamine excess in schizophrenia. Biol Psychiatry 2018;83:635-7. 9. Brugger SP, Angelescu I, Abi-Dargham A et al. Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance. Biol Psychiatry 2020;87:215-24. 10. Sydnor VJ, Roalf DR. A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: implications for studies of psychosis risk. Schizophr Res 2020;226:61-9. 11. Klosterkötter J, Schultze-Lutter F, Ruhrmann S. Kraepelin and psychotic prodromal conditions. Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl. 2):7484. 12. Debbané M, Eliez S, Badoud D et al. Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull 2015;41:S396-407. 13. Barrantes-Vidal N, Grant P, Kwapil TR. The role of schizotypy in the study of the etiology of schizophrenia spectrum disorders. Schizophr Bull 2015; 41:S408-16. 14. Nordentoft M, Thorup A, Petersen L et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006;83:29-40. 15. Fusar-Poli P, Bonoldi I, Yung AR et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012;69:220-9. 16. Cannon TD, Cornblatt B, McGorry P. The empirical status of the ultra highrisk (prodromal) research paradigm. Schizophr Bull 2007;33:661-4. 17. Bassett AS, Chow EWC. Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 2008;10:148-57. 18. Schneider M, Debbané M, Bassett AS et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry 2014;171:627-39. 19. Howes O, Bose S, Turkheimer FE et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 2011;168:1311-7. 20. de la Fuente-Sandoval C, Leon-Ortiz P, Azcárraga M et al. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol 2013;16:471-5. 21. Pillinger T, Osimo EF, Brugger S et al. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. Schizophr Bull 2019;45:1120-33. 22. Brugger SP, Howes OD. Heterogeneity and homogeneity of regional brain structure in schizophrenia. JAMA Psychiatry 2017;74:1104-11. 23. Nakagawa S, Poulin R, Mengersen K et al. Meta-analysis of variation: ecological and evolutionary applications and beyond. Methods Ecol Evol 2015; 6:143-52. 24. McCutcheon R, Pillinger T, Mizuno Y et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis. Mol Psychiatry 2021;26:1310-20. 25. Howes OD, Montgomery AJ, Asselin M-C et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009;66:13-20. 26. Mizrahi R, Addington J, Rusjan PM et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012;71:561-7. 27. Shotbolt P, Stokes PR, Owens SF et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med 2011;41:2331-8. 28. Brunelin J, d’Amato T, van Os J et al. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res 2010;181:130-5. 29. Wenneberg C, Glenthøj BY, Hjorthøj C et al. Cerebral glutamate and GABA levels in high-risk of psychosis states: a focused review and meta-analysis of 1H-MRS studies. Schizophr Res 2020;215:38-48. 30. Bossong MG, Antoniades M, Azis M et al. Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. JAMA Psychiatry 2019;76:199-207. 31. Rogdaki M, Hathway P, Gudbrandsen M et al. Glutamatergic function in a genetic high-risk group for psychosis: a proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. Eur Neuropsychopharmacol 2019;29:1333-42. 32. Legind CS, Broberg BV, Mandl RCW et al. Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1[H]spectroscopy twin study. Neuropsychopharmacology 2019;44:581-9. 33. Menschikov PE, Semenova NA, Ublinskiy MV et al. 1H-MRS and MEGAPRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients. Dokl Biochem Biophys 2016;468:168-72. 34. Provenzano FA, Guo J, Wall MM et al. Hippocampal pathology in clinical high-risk patients and the onset of schizophrenia. Biol Psychiatry 2020; 87:234-42. 35. Wenneberg C, Nordentoft M, Rostrup E et al. Cerebral glutamate and gamma-aminobutyric acid levels in individuals at ultra-high risk for psychosis and the association with clinical symptoms and cognition. Biol Psychiatry Cogn Neurosci Neuroimaging 2020;5:569-79. 36. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005;39:964-71. 37. Miller TJ, McGlashan TH, Rosen JL et al. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003;29:703-15. 38. Thompson JL, Urban N, Slifstein M et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 2013;18:9095. 39. Mizrahi R, Suridjan I, Kenk M et al. Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO. Neuropsychopharmacology 2013;38:673-82. 40. Bloomfield MAP, Morgan CJA, Egerton A et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2014;75:470-8. 41. Tziortzi AC, Searle GE, Tzimopoulou S et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011;54:264-77. 42. Howes OD, Bonoldi I, McCutcheon RA et al. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. Neuropsychopharmacology 2020;45:641-8. 43. Abi-Dargham A, Kegeles LS, Zea-Ponce Y et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [ 123 I]iodobenzamide. Biol Psychiatry 2004;55: 1001-6. 44. Egerton A, Chaddock CA, Winton-Brown TT et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry 2013;74:106-12. 45. Bloemen OJN, de Koning MB, Gleich T et al. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. Eur Neuropsychopharmacol 2013;23:126-32. 46. Tseng H-H, Watts JJ, Kiang M et al. Nigral stress-induced dopamine release in clinical high risk and antipsychotic-naïve schizophrenia. Schizophr Bull 2018;44:542-51. 47. Girgis RR, Slifstein M, Brucato G et al. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study. Mol Psychiatry (in press). 48. Thompson JL, Rosell DR, Slifstein M et al. Amphetamine-induced striatal dopamine release in schizotypal personality disorder. Psychopharmacology 2020;237:2649-59. 49. Huttunen J, Heinimaa M, Svirskis T et al. Striatal dopamine synthesis in firstdegree relatives of patients with schizophrenia. Biol Psychiatry 2008;63:114-7. 50. Kasanova Z, Ceccarini J, Frank MJ et al. Intact striatal dopaminergic modulation of reward learning and daily-life reward-oriented behavior in firstdegree relatives of individuals with psychotic disorder. Psychol Med 2018; 48:1909-14. 51. van Duin EDA, Kasanova Z, Hernaus D et al. Striatal dopamine release and impaired reinforcement learning in adults with 22q11.2 deletion syndrome. Eur Neuropsychopharmacol 2018;28:732-42. 52. Rogdaki M, Devroye C, Ciampoli M et al. Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Mol Psychiatry (in press). 53. Vingerhoets C, Bloemen OJN, Boot E et al. Dopamine in high-risk populations: a comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. Psychiatry Res Neuroimaging 2018;272:6570. 54. Hirvonen J, van Erp TGM, Huttunen J et al. Striatal dopamine D 1 and D 2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res 2006;146:13-20. 55. Lee KJ, Lee JS, Kim SJ et al. Loss of asymmetry in D 2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr Scand 2008;118:200-8. 56. Egerton A, Stone JM, Chaddock CA et al. Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology 2014;39:2891-9. 57. Modinos G, Egerton A, McLaughlin A et al. Neuroanatomical changes in people with high schizotypy: relationship to glutamate levels. Psychol Med 2018;48:1880-9. 58. Byun MS, Choi JS, Yoo SY et al. Depressive symptoms and brain metabolite alterations in subjects at ultra-high risk for psychosis: a preliminary study. Psychiatry Investig 2009;6:264-71. 59. Natsubori T, Inoue H, Abe O et al. Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. Schizophr Bull 2014;40:1128-39. 60. de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X et al. Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy. Int J Neuropsychopharmacol 2015;19:pyv105. 61. Liemburg E, Sibeijn-Kuiper A, Bais L et al. Prefrontal NAA and Glx levels in different stages of psychotic disorders: a 3T 1 H-MRS study. Sci Rep 2016;6: 21873. 62. Wang J, Tang Y, Zhang T et al. Reduced γ-aminobutyric acid and glutamate+ glutamine levels in drug-naïve patients with first-episode schizophrenia but not in those at ultrahigh risk. Neural Plast 2016;2016:3915703. 63. Da Silva T, Hafizi S, Rusjan PM et al. GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. J Psychiatry Neurosci 2019;44:111-1. 64. Stone JM, Day F, Tsagaraki H et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 2009;66:533-9. 65. Bloemen OJN, Gleich T, de Koning MB et al. Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biol Psychiatry 2011;70:e1-2. 66. Nenadic I, Dietzek M, Schönfeld N et al. Brain structure in people at ultrahigh risk of psychosis, patients with first-episode schizophrenia, and healthy controls: a VBM study. Schizophr Res 2015;161:169-76. 67. Shakory S, Watts JJ, Hafizi S et al. Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. Neuropsychopharmacology 2018;43:2249-55. 68. Wood SJ, Kennedy D, Phillips LJ et al. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 2010;52:62-8. 69. de la Fuente-Sandoval C, León-Ortiz P, Favila R et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011;36:1781-91. 70. Tibbo P, Hanstock C, Valiakalayil A et al. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004;161:1116-8. 71. Purdon SE, Valiakalayil A, Hanstock CC et al. Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-oX) scores and genetic risk for schizophrenia. Schizophr Res 2008;99:218-24. 72. Lutkenhoff ES, van Erp TG, Thomas MA et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 2010;15:308-18. 73. Vingerhoets C, Tse DHY, van Oudenaren M et al. Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: a randomized double-blind 7-Tesla pharmacological MRS study. J Psychopharmacol 2020;34:856-63. 74. Block W, Bayer TA, Tepest R et al. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett 2000;289:147-51. 75. Yoo SY, Yeon S, Choi C-H et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res 2009;111:86-93. 76. da Silva Alves F, Boot E, Schmitz N et al. Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLoS One 2011;6:e21685. 77. Capizzano AA, Nicoll Toscano JL, Ho BC. Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands. Schizophr Res 2011;131:4-10. 78. Tandon N, Bolo NR, Sanghavi K et al. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res 2013;148:59-66. 79. Keshavan MS, Dick RM, Diwadkar VA et al. Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study. Schizophr Res 2009;115:88-93. 80. Thakkar KN, Rösler L, Wijnen JP et al. 7T proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings. Biol Psychiatry 2017;81:525-35. 81. Valli I, Howes OD, Tyrer P et al. Longitudinal PET imaging in a patient with schizophrenia did not show marked changes in dopaminergic function with relapse of psychosis. Am J Psychiatry 2008;165:1613-4. 82. Howes O, Bose S, Turkheimer F et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011;16:885-6. 83. Laruelle M, Abi-Dargham A, Gil R et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:5672. 84. Merritt K, McGuire P, Egerton A et al. Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis. JAMA Psychiatry (in press). 85. McCutcheon R, Nour MM, Dahoun T et al. Mesolimbic dopamine function is related to salience network connectivity: an integrative positron emission tomography and magnetic resonance study. Biol Psychiatry 2019;85:368-78. 86. Berry AS, Shah VD, Furman DJ et al. Dopamine synthesis capacity is associated with D2/3 receptor binding but not dopamine release. Neuropsychopharmacology 2018;43:1201-11. 87. Nour MM, McCutcheon R, Howes OD. The relationship between dopamine synthesis capacity and release: implications for psychosis. Neuropsychopharmacology 2018;43:1195-6. 88. Cannon TD, Yu C, Addington J et al. An individualized risk calculator for research in prodromal psychosis. Am J Psychiatry 2016;173:980-8. 89. Schifani C, Tseng H-H, Kenk M et al. Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. Brain 2018;41:18979.